Chiron Refining GMP Remediation Plan Following FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The FDA letter requests additional information on "investigations into cGMP deviations and the design and conduct of studies to aid investigations," Chiron says. The letter follows an inspection of Chiron's Liverpool facility where Fluvirin is produced.